Filgrastim -- and then what happens?

Welcome Zarxio. While nothing is “easy” when it comes to drug development, many view this initial Sandoz experience as forecasting clear skies and fair winds for every biosimilar put in front of the agency for consideration. If you believe that, there’s a bridge in Brooklyn you might find of interest.
Source: drugwonks.com Blog - Category: Pharmaceuticals Source Type: blogs